重组人生长激素对矮小症进行治疗的临床疗效及其安全性分析

Clinical efficacy and safety of recombinant human growth hormone in the treatment of short stature

目的分析重组人生长激素对矮小症进行治疗的临床疗效及其安全性。方法以2019年1月-2020年1月来我院就诊的158例矮小症患儿为研究对象,应用随机数字表法分为对照组与观察组,对照组患儿给予常规营养支持及治疗,观察组患儿给予重组人生长激素治疗,治疗一年后以治疗前后患儿身高,生长速度、骨龄、血清胰岛素祥生长因子1(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)水平为研究依据,同时对比两组患儿治疗期间的不良反应发生情况。结果治疗前两组患儿身高、生长速度、骨龄皆不存在显著差异,治疗后观察组患儿身高、生长速度、骨龄情况优于对照组患儿,差异明显,具备统计学价值;治疗前观察组患儿IGF-1.IGFBP-3水平不存在显著差异,治疗后观察组患儿IGF-1.1GFBP-3水平优于对照组患儿,差异显著;对照组患儿治疗中不良反应发生率高于观察组患儿,差异显著。结论重组人生长激素对矮小症进行治疗的临床疗效较为明显,同时不良反应发生率相对较低,值得在临床实践中予以推广.

Objective To analyze the elinical efficacy and safety of recombinant human growth hormone in the treatment of short stature.Methods 158 children with short stature treated in our hospital from January 2019 to January 2020 were randomly divided into the control group and the observation group.The control group was given routine nutritional support and treatment,while the observation group was given recombinant human growth hormone treatment.After one year of treatment,the height,growth rate,bone age of the children before and after treatment were compared The serum levels of insulin-like growth factor-1(ICF-1)and insulin-like growth factor binding protein-3(CFBP-3)were used as the research basis,and the adverse reactions of the Iwo groups during the treatment were compared.Results Before treatment,there was no significant difference in height,growth speed and bone age between the lwo groups.After treatment,the height,growth speed and bone age of the observation group were better than those of the control group,with significant difference and statistical value;Before treatment,there was no significant dfference in the levels of IGF-I and ICFBP-3 in the observation group.After treatment,the levels of ICF-I and ICFBP-3 in the observation group were better than those in the control group,with significant difference;The ineidence of adverse reactions in the control group was higher than thal in the observation group,the difference was significant.Conclus ion The elinical ffiracy of reombinant human growth hormone in the treatment of short stature is obvious,and the ineidence of adverse reactions is relatively low,which is worthy of promotion in elinical practice.